1
NR 566 FINAL EXAM NEWEST 2026
ACTUAL EXAM TEST BANK| NR566
ADVANCED PHARMACOLOGY FOR CARE
OF THE FAMILY FINAL EXAM REVIEW
WITH COMPLETE 250+ REAL EXAM
QUESTIONS AND CORRECT DETAILED
ANSWERS (VERIFIED ANSWERS)
ALREADY GRADED A+ (BRAND NEW!!)
SECTION 1: WOMEN'S HEALTH & HORMONAL THERAPY
1. A 58-year-old patient asks why long-term hormone therapy (HT) is
not usually the first choice for osteoporosis prevention. Which
response is BEST?
A) HT prevents bone loss permanently even after it is stopped
B) Bone mass rapidly decreases after stopping HT, so ongoing
lifelong use would increase harm risk
C) HT only works if started before the first missed menstrual cycle
D) HT prevents fractures only when combined with calcium
supplementation
Answer: B
,2
Rationale: HT decreases postmenopausal bone loss, but bone mass
rapidly declines after discontinuation, so maintaining benefit would
require lifelong therapy with greater risk of harm . This makes HT
less favorable as a first-line option for osteoporosis prevention
compared to bisphosphonates.
2. Which medication is listed as an effective alternative to HT for
osteoporosis prevention?
A) Raloxifene
B) Methimazole
C) Acyclovir
D) Rasagiline
Answer: A
Rationale: Raloxifene is a selective estrogen receptor modulator
(SERM) specifically listed as an effective alternative to HT for
reducing postmenopausal bone loss and fracture risk . It provides
bone benefits without some of the risks associated with estrogen
therapy.
3. A patient with an intact uterus is prescribed systemic estrogen for
hot flashes. Which additional therapy is MOST consistent with the
goal for progestins in hormone therapy?
A) Add a progestin to reduce endometrial hyperplasia risk
B) Add a progestin to enhance the hot flash relief
,3
C) Add a progestin to reduce breast cancer risk
D) No additional therapy is needed
Answer: A
Rationale: For women with an intact uterus, unopposed systemic
estrogen increases the risk of endometrial hyperplasia and cancer.
Adding a progestin counteracts this risk and is standard practice
when prescribing systemic estrogen to women with a uterus .
4. Which patient would be prescribed progestin-only therapy
according to the study guide?
A) A woman with an intact uterus on systemic estrogen
B) A woman who has undergone hysterectomy
C) A woman seeking contraception only
D) A woman with a history of breast cancer
Answer: B
Rationale: Progestins should not be prescribed for women who have
undergone hysterectomy as there is no uterus to protect from
unopposed estrogen effects . In these patients, estrogen alone is
appropriate.
5. A patient wants treatment primarily for vulvovaginal atrophy
symptoms. Which option is MOST aligned with local estrogen
options?
, 4
A) Vaginal inserts, creams, or rings
B) IV estrogen infusion
C) IM estrogen injections for routine therapy
D) Oral estradiol combined with a progestin
Answer: A
Rationale: Intravaginal estrogens (inserts, creams, rings) are local
options used primarily for vulvar and vaginal atrophy associated with
menopause . These deliver low-dose estrogen locally with minimal
systemic absorption.
6. Which statement about Femring is MOST accurate according to
the guide?
A) It is used only for local vulvovaginal atrophy
B) It is used for systemic effects to control hot flashes and night
sweats
C) It is contraindicated in all menopause patients
D) It is an oral estrogen formulation
Answer: B
Rationale: Femring is a vaginal ring that provides systemic estrogen
effects to control hot flashes and night sweats, in addition to some
local effects . It is not limited to local atrophy treatment.
NR 566 FINAL EXAM NEWEST 2026
ACTUAL EXAM TEST BANK| NR566
ADVANCED PHARMACOLOGY FOR CARE
OF THE FAMILY FINAL EXAM REVIEW
WITH COMPLETE 250+ REAL EXAM
QUESTIONS AND CORRECT DETAILED
ANSWERS (VERIFIED ANSWERS)
ALREADY GRADED A+ (BRAND NEW!!)
SECTION 1: WOMEN'S HEALTH & HORMONAL THERAPY
1. A 58-year-old patient asks why long-term hormone therapy (HT) is
not usually the first choice for osteoporosis prevention. Which
response is BEST?
A) HT prevents bone loss permanently even after it is stopped
B) Bone mass rapidly decreases after stopping HT, so ongoing
lifelong use would increase harm risk
C) HT only works if started before the first missed menstrual cycle
D) HT prevents fractures only when combined with calcium
supplementation
Answer: B
,2
Rationale: HT decreases postmenopausal bone loss, but bone mass
rapidly declines after discontinuation, so maintaining benefit would
require lifelong therapy with greater risk of harm . This makes HT
less favorable as a first-line option for osteoporosis prevention
compared to bisphosphonates.
2. Which medication is listed as an effective alternative to HT for
osteoporosis prevention?
A) Raloxifene
B) Methimazole
C) Acyclovir
D) Rasagiline
Answer: A
Rationale: Raloxifene is a selective estrogen receptor modulator
(SERM) specifically listed as an effective alternative to HT for
reducing postmenopausal bone loss and fracture risk . It provides
bone benefits without some of the risks associated with estrogen
therapy.
3. A patient with an intact uterus is prescribed systemic estrogen for
hot flashes. Which additional therapy is MOST consistent with the
goal for progestins in hormone therapy?
A) Add a progestin to reduce endometrial hyperplasia risk
B) Add a progestin to enhance the hot flash relief
,3
C) Add a progestin to reduce breast cancer risk
D) No additional therapy is needed
Answer: A
Rationale: For women with an intact uterus, unopposed systemic
estrogen increases the risk of endometrial hyperplasia and cancer.
Adding a progestin counteracts this risk and is standard practice
when prescribing systemic estrogen to women with a uterus .
4. Which patient would be prescribed progestin-only therapy
according to the study guide?
A) A woman with an intact uterus on systemic estrogen
B) A woman who has undergone hysterectomy
C) A woman seeking contraception only
D) A woman with a history of breast cancer
Answer: B
Rationale: Progestins should not be prescribed for women who have
undergone hysterectomy as there is no uterus to protect from
unopposed estrogen effects . In these patients, estrogen alone is
appropriate.
5. A patient wants treatment primarily for vulvovaginal atrophy
symptoms. Which option is MOST aligned with local estrogen
options?
, 4
A) Vaginal inserts, creams, or rings
B) IV estrogen infusion
C) IM estrogen injections for routine therapy
D) Oral estradiol combined with a progestin
Answer: A
Rationale: Intravaginal estrogens (inserts, creams, rings) are local
options used primarily for vulvar and vaginal atrophy associated with
menopause . These deliver low-dose estrogen locally with minimal
systemic absorption.
6. Which statement about Femring is MOST accurate according to
the guide?
A) It is used only for local vulvovaginal atrophy
B) It is used for systemic effects to control hot flashes and night
sweats
C) It is contraindicated in all menopause patients
D) It is an oral estrogen formulation
Answer: B
Rationale: Femring is a vaginal ring that provides systemic estrogen
effects to control hot flashes and night sweats, in addition to some
local effects . It is not limited to local atrophy treatment.
